Back to results
US 2021/0060169 A1Published application
Il-2 variant
AssigneeKyowa Kirin Co., Ltd.
InventorsMasahiro IKEDA, Shinpei YAMAGUCHI, Masumi MURAKAMI, Hideyuki ONODERA
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeKyowa Kirin Co., Ltd.
InventorsMasahiro IKEDA, Shinpei YAMAGUCHI, Masumi MURAKAMI, Hideyuki ONODERA
Estimating the term…
An object of the present invention is to provide a novel IL-2 variant which has improved selectivity for IL-2Rαβγ and selectively activates Tregs. The present invention relates to an IL-2 variant, a method for producing the IL-2 variant, a composition and a therapeutic agent for an immune disease, comprising the IL-2 variant, a method for increasing selectivity of IL-2 for IL-2Rαβγ, a method for improving an affinity of IL-2 for an IL-2Rα subunit, a method of reducing an affinity of IL-2 for at least one of an IL-2Rβ subunit and an IL-2Rγ subunit, and a method for selectively activating regulatory T cells.
An Interleukin-2 (IL 2) variant having improved selectivity for an IL-2 receptor (IL-2R)αβγ, wherein the IL-2 variant is a polyethylene glycol (PEG)-bound IL-2 variant in which PEG is bound to at least one amino acid residue selected from the group consisting of amino acid residues at positions 4, 5, 6, 7, 8, 60, 78, 79, 99, 100, 101, and 129 in the amino acid sequence of the IL-2 variant.
2-11. (canceled)
(canceled)
29-57. (canceled)
Dependencies are inferred from the claim text.